600993.SH
马应龙
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 22.73
−1.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.9B | 3.9B | 3.7B | 3.1B | 3.5B |
| Cost of Revenue | 2.0B | 2.0B | 2.0B | 1.8B | 2.0B |
| Gross Profit | 1.9B | 1.9B | 1.7B | 1.3B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 76.3M | 78.1M | 66.7M | 69.0M | 77.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 130.5M | 132.0M | 114.4M | 110.0M | 105.3M |
| Selling & Marketing Expense | 1.0B | 1.0B | 936.9M | 715.2M | 780.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.2B | 1.2B | 1.1B | 874.2M | 943.7M |
| Cost and Expenses | 3.2B | 3.2B | 3.1B | 2.7B | 3.0B |
| Operating Income (EBIT) | 728.9M | 719.9M | 666.8M | 536.6M | 555.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 717.8M | 709.0M | 657.6M | 524.7M | 559.1M |
| Income Tax Expense | 102.8M | 103.3M | 109.3M | 72.9M | 79.8M |
| Bottom Line | |||||
| Net Income | 590.5M | 581.5M | 528.1M | 443.3M | 478.6M |
| Earnings from Cont. Ops | 615.0M | 605.7M | 548.3M | 451.8M | 479.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 590.5M | 581.5M | 528.1M | 443.3M | 478.6M |
| Per Share | |||||
| Basic EPS | CN¥1.37 | CN¥1.35 | CN¥1.23 | CN¥1.03 | CN¥1.11 |
| Diluted EPS | CN¥1.37 | CN¥1.35 | CN¥1.23 | CN¥1.03 | CN¥1.11 |
| Revenue Per Share | CN¥9.01 | CN¥8.98 | CN¥8.68 | CN¥7.29 | CN¥8.19 |
| Shares | |||||
| Basic Shares Outstanding | 433.8M | 430.7M | 429.3M | 430.3M | 431.1M |
| Diluted Shares Outstanding | 433.8M | 430.7M | 429.3M | 430.3M | 431.1M |
| Profitability Metrics | |||||
| EBITDA | — | 791.2M | 723.8M | 595.6M | 612.3M |
| D&A | — | 71.3M | 56.9M | 59.0M | 56.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026